LIN YING LIU
Cosmetology in Rockville, MD
License number
Virginia 1201115906
Issued Date
Jan 10, 2011
Expiration Date
Jan 31, 2015
Category
Cosmetologist License
Type
Cosmetologist
Address
Address
Rockville, MD
Professional information
Enzyme Treatment
US Patent:
6780628, Aug 24, 2004
Filed:
Dec 8, 2000
Appl. No.:
09/731971
Inventors:
David M. Anderson - Rockville MD
Lin Liu - Rockville MD
Humg-Yu Hsiao - Rockville MD
Douglas W. Fodge - Derwood MD
Lin Liu - Rockville MD
Humg-Yu Hsiao - Rockville MD
Douglas W. Fodge - Derwood MD
Assignee:
Chemgen Corporation - Gaithersburg MD
International Classification:
A23L 131
US Classification:
435198, 435 4, 435 6, 435183, 435195, 426 2, 426 56, 426531
Abstract:
Enzymes of a particular class, characterized by the ability to cleave a linkage that effects release of a cell-surface protein or carbohydrate, which does not contain an anti-infection agent, display significant anti-infectious activity. Upon oral administration, these enzymes are effective, for example, in the treatment of digestive tract infections in humans and in animals. In the latter, there are benefits of significantly improved growth rate, feed efficiency, and overall health.
Vectors, Cells And Processes For Pyrimidine Deoxyribonucleosides Production
US Patent:
6777209, Aug 17, 2004
Filed:
Mar 6, 2002
Appl. No.:
10/018878
Inventors:
David Martin Anderson - Rockville MD
Lin Liu - Rockville MD
Sergey Podkovyrov - Gaithersburg MD
Baomin Wang - Rockville MD
Lin Liu - Rockville MD
Sergey Podkovyrov - Gaithersburg MD
Baomin Wang - Rockville MD
Assignee:
SmithKline Beecham Corporation - Philadelphia PA
International Classification:
C12N 120
US Classification:
435 87, 4353201, 435 691, 435325, 4352523, 435194, 435189, 435227, 43525233, 536 232, 530350
Abstract:
Novel DNA constructs and host cells comprising the same are disclosed. DNA constructs comprise a transcription unit (e. g. operon) comprising DNA sequences encoding for ribonucleotide reductase and thioredoxin or a uridine kinase gene and/or a dCTP deaminase gene. In preferred embodiments the constructs comprising DNA sequences encoding for ribonucleotide reductase and thioredoxin further comprise DNA sequences encoding for thymidylate synthase and/or transcription units comprising sequences encoding for uridine kinase preferably together with dCTP deaminase. In particularly preferred embodiments, the host cells comprise constructs having all of the above characteristics wherein the host cell displays repressed or no uracil DNA glycosylase activity. This may be achieved by removal of the host cell ung gene. Use of host cells in the manufacture of pyrimidine deoxyribonucleotides e. g.
Vectors, Cells And Processes For Pyrimidine Deoxyribonucleosides Production
US Patent:
7387893, Jun 17, 2008
Filed:
Aug 9, 2004
Appl. No.:
10/914529
Inventors:
David Martin Anderson - Rockville MD, US
Lin Liu - Rockville MD, US
Sergey Podkovyrov - Gaithersburg MD, US
Baomin Wang - Rockville MD, US
Lin Liu - Rockville MD, US
Sergey Podkovyrov - Gaithersburg MD, US
Baomin Wang - Rockville MD, US
Assignee:
SmithKline Beecham Corporation - Philadelphia PA
International Classification:
C12N 15/00, C12N 1/20, C12N 5/10, C07H 21/00, C12N 9/02, C12N 9/12, C12N 9/78, C12Q 1/26, C12P 21/06, C07K 14/00
US Classification:
4353201, 4352523, 435325, 43525233, 435189, 435 25, 435 691, 435194, 435227, 536 232, 530350
Abstract:
Novel DNA constructs and host cells comprising the same are disclosed. DNA constructs comprise a transcription unit (e. g. operon) comprising DNA sequences encoding for ribonucleotide reductase and thioredoxin or a uridine kinase gene and/or a dCTP deaminase gene. In preferred embodiments the constructs comprising DNA sequences encoding for ribonucleotide reductase and thioredoxin further comprise DNA sequences encoding for thymidylate synthase and/or transcription units comprising sequences encoding for uridine kinase preferably together with dCTP deaminase. In particularly preferred embodiments, the host cells comprise constructs having all of the above characteristics wherein the host cell displays repressed or no uracil DNA glycosylase activity. This may be achieved by removal of the host cell ung gene. Use of host cells in the manufacture of pyrimidine deoxyribonucleotides e. g.
Enzymes For Reduced Immunological Stress
US Patent:
2011017, Jul 21, 2011
Filed:
Mar 25, 2011
Appl. No.:
13/072131
Inventors:
David M. Anderson - Rockville MD, US
Humg-Yu Hsiao - Rockville MD, US
Lin Liu - Rockville MD, US
Humg-Yu Hsiao - Rockville MD, US
Lin Liu - Rockville MD, US
International Classification:
A23K 1/165, A23K 1/18
US Classification:
426 2, 426 61
Abstract:
Compositions suitable for oral administration to an animal comprising at least one immune stress-reducing enzyme in an amount effective to decrease the level of positive acute phase protein in an animal, increase the level of negative acute phase protein in an animal, and/or improve animal growth performance is provided, as are methods using such compositions. The compositions include animal feed compositions, liquid compositions other than animal feed, and solid compositions other than animal feed.
Enzymes For Reduced Immunological Stress
US Patent:
2011017, Jul 14, 2011
Filed:
Mar 25, 2011
Appl. No.:
13/072123
Inventors:
David M. Anderson - Rockville MD, US
Humg-Yu Hsiao - Rockville MD, US
Lin Liu - Rockville MD, US
Humg-Yu Hsiao - Rockville MD, US
Lin Liu - Rockville MD, US
International Classification:
A23K 1/165
US Classification:
426 2, 426 61
Abstract:
Compositions suitable for oral administration to an animal comprising at least one immune stress-reducing enzyme in an amount effective to decrease the level of positive acute phase protein in an animal, increase the level of negative acute phase protein in an animal, and/or improve animal growth performance is provided, as are methods using such compositions. The compositions include animal feed compositions, liquid compositions other than animal feed, and solid compositions other than animal feed.
Enzymes For Reduced Immunological Stress
US Patent:
2011017, Jul 14, 2011
Filed:
Mar 25, 2011
Appl. No.:
13/072109
Inventors:
DAVID M. ANDERSON - ROCKVILLE MD, US
HUMG-YU HSIAO - ROCKVILLE MD, US
LIN LIU - ROCKVILLE MD, US
HUMG-YU HSIAO - ROCKVILLE MD, US
LIN LIU - ROCKVILLE MD, US
International Classification:
A23K 1/165
US Classification:
426 2, 426 61
Abstract:
Compositions suitable for oral administration to an animal comprising at least one immune stress-reducing enzyme in an amount effective to decrease the level of positive acute phase protein in an animal, increase the level of negative acute phase protein in an animal, and/or improve animal growth performance is provided, as are methods using such compositions. The compositions include animal feed compositions, liquid compositions other than animal feed, and solid compositions other than animal feed.
Enzymes For Reduced Immunological Stress
US Patent:
7914782, Mar 29, 2011
Filed:
Dec 14, 2006
Appl. No.:
11/610572
Inventors:
David M. Anderson - Rockville MD, US
Humg-Yu Hsiao - Rockville MD, US
Lin Liu - Rockville MD, US
Humg-Yu Hsiao - Rockville MD, US
Lin Liu - Rockville MD, US
Assignee:
Chemgen Corporation - Gaithersburg MD
International Classification:
A61K 38/47
US Classification:
424 9461
Abstract:
Compositions suitable for oral administration to an animal comprising at least one immune stress-reducing enzyme in an amount effective to decrease the level of positive acute phase protein in an animal, increase the level of negative acute phase protein in an animal, and/or improve animal growth performance is provided, as are methods using such compositions. The compositions include animal feed compositions, liquid compositions other than animal feed, and solid compositions other than animal feed.
Composition Comprising Beta-Mannanase
US Patent:
7723091, May 25, 2010
Filed:
May 28, 2004
Appl. No.:
10/855416
Inventors:
David M. Anderson - Rockville MD, US
Lin Liu - Rockville MD, US
Humg-Yu Hsiao - Rockville MD, US
Douglas W. Fodge - Derwood MD, US
Lin Liu - Rockville MD, US
Humg-Yu Hsiao - Rockville MD, US
Douglas W. Fodge - Derwood MD, US
Assignee:
Chemgen Corporation - Gaithersburg MD
International Classification:
C12N 9/24, C12N 9/00, C12Q 1/00, C12Q 1/68, A23L 1/31, C07H 21/04
US Classification:
435200, 426 58, 435 4, 435 6, 435 691, 435183, 530350, 536 232
Abstract:
Enzymes of a particular class, characterized by the ability to cleave a linkage that effects release of a cell-surface protein or carbohydrate, which does not contain an anti-infection agent, display significant anti-infectious activity. Upon oral administration, these enzymes are effective, for example, in the treatment of digestive tract infections in humans and in animals. In the latter, there are benefits of significantly improved growth rate, feed efficiency, and overall health.